Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT630 vs Adalimumab in Plaque Psoriasis
NCT03927352Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SCT630 in plaque psoriasis (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16. Status: unknown.
02
Drugs
SCT630
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03927352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927352.